# US 2025/0154276 A1 · Application of cd45 as biomarker in screening effectiveness and precision of cd26 antibody or derivative thereof in treating tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154276 A1
- Document ID: US20250154276A1
- Status: Published application
- Kind: A1
- Application number: 18/834,319
- Filed: 2023-01-17
- Published: 2025-05-15
- Earliest claimed: 2022-01-30
- Assignees: Zonhon Biopharma Institute Inc.
- Applicants: Zonhon Biopharma Institute, Inc.
- Inventors: Bruce Yong MA; Peipei CAO; Chennan GE; Jianhua HANG
- Web page: https://patentgrep.com/patent/US20250154276A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4247: {Proteinases}
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/40: against enzymes
- C12N 15/86: Viral vectors
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/575: for cancer
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/13: Antibody-based
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- G01N 2333/70589: CD45
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

CD45 is used as a biomarker in screening the effectiveness of a CD26 antibody or derivative thereof in treating tumors in a test subject. Specifically, when CD45 is not expressed or has low expression, determining that the treatment of the test subject who has received a CD26 antibody or a derivative thereof is effective or has a high probability of being effective; and when CD45 expression is high or relatively high, determining that the treatment of the test subject who has received a CD26 antibody or a derivative thereof is ineffective or has a high probability of being ineffective. It has been found that CD26 acts as a new mechanism for treatment effectiveness and precision of novel tumor immunotherapy targets.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method of using a CD26 antibody or a derivative thereof to treat a tumor with CD26 expression but without CD45 expression, or a tumor with CD26 expression and with low CD45 expression, wherein the tumor is a solid tumor or a hematological tumor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the tumor is a solid tumor.

### Claim 13 (depends on 11)

The method of claim 11, wherein the tumor is selected from the group consisting of: a renal cancer, a lung cancer, and a prostate cancer.

### Claim 14 (depends on 13)

The method of claim 13, wherein the lung cancer comprise a lung squamous carcinoma.

### Claim 15 (depends on 11)

The method of claim 11, the CD26 antibody is a full-length antibody, a Fab fragment, a FV fragment, a linear antibody, a single-chain antibody, a nanobody, a bispecific antibody, or a multi-specific antibody that specifically binds to CD26.

### Claim 16 (depends on 11)

The method of claim 11, the derivative of CD26 antibody is a Car-T targeting CD26.

### Claim 17 (depends on 11)

The method of claim 11, the derivative of CD26 antibody is an rAAV vector comprising a gene encoding anti-CD26 antibody.

### Claim 18

A method for screening the effectiveness of treatment with CD26 antibody or derivative thereof to a subject, which comprises a step of detecting the expression of CD45 in lesions; when CD45 has a low expression, the treatment with CD26 antibody or derivative thereof to the subject is effective or has a high probability of effectiveness; when CD45 has a high expression, the treatment with CD26 antibody or derivative thereof to the subject is ineffective or has a high probability of ineffectiveness.

### Claim 19 (depends on 18)

The method of claim 18, wherein a CD45 antigen or an anti-CD45 antibody is used to screen the effectiveness of treatment with CD26 antibody or derivative thereof to the subject.

### Claim 20 (depends on 18)

The method of claim 18, wherein the subject has a tumor, and the tumor is a solid tumor or a hematological tumor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the tumor is selected from the group consisting of: a renal cancer, a lung cancer, and a prostate cancer.

### Claim 22 (depends on 21)

The method of claim 21, wherein the lung cancer comprise a lung squamous carcinoma.

### Claim 23

A method for screening the effectiveness of treatment with CD26 antibody or derivative thereof to a subject, which comprises a step of detecting the expression of CD45 in lesions; when CD45 has no expression, the treatment with CD26 antibody or derivative thereof to the subject is effective or has a high probability of effectiveness; when CD45 has an expression, the treatment with CD26 antibody or derivative thereof to the subject is ineffective or has a high probability of ineffectiveness.

### Claim 24 (depends on 23)

The method of claim 23, wherein a CD45 antigen or an anti-CD45 antibody is used to screen the effectiveness of treatment with CD26 antibody or derivative thereof to the subject.

### Claim 25 (depends on 23)

The method of claim 23, wherein the subject has a tumor, and the tumor is a solid tumor or a hematological tumor.

### Claim 26 (depends on 25)

The method of claim 25, wherein the tumor is selected from the group consisting of: a renal cancer, a lung cancer, and a prostate cancer.

### Claim 27 (depends on 26)

The method of claim 26, wherein the lung cancer comprise a lung squamous carcinoma.
